EMEA-003083-PIP01-21

Table of contents

Key facts

Active substance
Humanised IgG2k Fc-modified bispecific antibody against CD3 and BCMA (PF-06863135)
Therapeutic area
Oncology
Decision number
P/0564/2021
PIP number
EMEA-003083-PIP01-21
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of Multiple Myeloma
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Pfizer Europe MA EEIG

 E-mail: pip_enquiries@pfizer.com
Tel. +44 1304646607

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating